Navigation Links
Armed antibody triggers remissions for Hodgkin's lymphoma
Date:11/3/2010

HOUSTON ― An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

"That level of objective responses to a drug is impressive for a Phase I trial," said study lead author Anas Younes, M.D., professor in The University of Texas MD Anderson Cancer Center's Department of Lymphoma/Myeloma. "These encouraging results are being confirmed in a large phase II trial, the results of which are expected to be released in December.

"There hasn't been a new drug considered for Hodgkin lymphoma in 30 years," Younes said. "The potential impact on years of life saved is huge because the median age for this disease is only 32."

Phase I trials are mainly designed to find a maximum tolerated dose for an investigational therapy and to determine the type and severity of side effects that may accompany a drug. They enroll patients who have received standard treatments and have no other therapeutic options.

Brentuximab vedotin (SGN-35), the drug used in the clinical trial, consists of an antibody that targets the CD30 cell surface protein attached to a drug that blocks a class of proteins crucial to cell division. CD30 is expressed on Hodgkin lymphoma and anaplastic large-cell lymphoma (ALCL) cells, Younes said, with normal expression limited to about 1 percent of T cells and other immune system components.

A total of 45 patients enrolled, 42 with Hodgkin lymphoma, two with ALCL and one with angioimmunoblastic T-cell lymphoma. They had undergone a median of three previous chemotherapy regimens and 73 percent had received blood stem cell transplants.

The investigators determined a maximum-tolerated intravenous dose of 1.8 mg per kilogram of body weight every three weeks. Side effects at that dose w
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences
2. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
3. Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
4. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
5. BioWa and NKTT Announce Licensing of BioWas POTELLIGENT(R) Technology For Use in Antibody Research and Development
6. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
7. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
8. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
9. arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work
10. First human gets new antibody aimed at hepatitis C virus
11. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... (OTC Bulletin Board: CSBR), a development stage,biotechnology company, ... of the Head and Neck Cancer Research Division ... as Chairman of the Board,replacing James Martell who ... was appointed to serve on the Company,s Board ...
... data show preferential, activity of adecatumumab on inhibiting ... 169 patients treated with adecatumumab demonstrate an ... of immunogenicity of the antibody, BETHESDA, Md., Oct. 23 ... on the development of,novel, proprietary antibody-based products for the treatment ...
... 23 Coordinating and timing,activities is a top ... of clinical trials. Marketers, who have the,primary responsibility ... "worry about competitors stealing your thunder, but also ... states one,interviewed executive. According to a Best ...
Cached Biology Technology:Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 2Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 3Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 2Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 5Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams 2
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
(Date:8/28/2014)... app called TX Invasives is now available from the ... Texas at Austin for identifying harmful non-native plant, insect ... in the United States cause about $137 billion in ... crops, clog waterways, kill native plants and more. , ... for reporting where invasive species occur, we,re more likely ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Ready for mating at the right time 2Ready for mating at the right time 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... by researchers David General of the Palawan State University , ... Zoology , Harvard University has led to the discovery of nine ... Philippines. Another two new genera were discovered by other researchers in ... jubilee issue of the open access journal Zookeys ...
... of the site of a spent nuclear fuel repository ... the International Journal of Environmental Technology and Management, the ... positive opinion on the location of such facilities than ... of nuclear waste around the globe are relatively small, ...
... Spanish . , Project PreDiCT-TB is ... the European pharmaceutical industry in the hopes of studying ... that affects nearly nine million people throughout the world. ... trials (,in vitro, and ,in vivo,) that will provide ...
Cached Biology News:An ant scientist's picnic: The highly diverse ant fauna of the Philippines 2Where to put nuclear waste? 2Research on improvements in diagnosing and treating tuberculosis 2Research on improvements in diagnosing and treating tuberculosis 3
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Biology Products: